Nu­vig rais­es $161M as it pre­pares for Phase 2 study in hot au­toim­mune field

An im­munomod­u­la­to­ry start­up called Nu­vig Ther­a­peu­tics an­nounced a $161 mil­lion Se­ries B amid ris­ing com­pe­ti­tion to de­vel­op new and bet­ter au­toim­mune med­i­cines.

Nu­vig, based in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER